Abstract
Abstract 4147907: Validation of PAINESD Score to Predict Outcomes of Catheter ablation of Structural Ventricular Tachycardia
Circulation (New York, N.Y.), Vol.150(Suppl_1), pp.A4147907-A4147907
11/12/2024
DOI: 10.1161/circ.150.suppl_1.4147907
Abstract
Background: PAINESD score was established as a predictor of periprocedural acute hemodynamic instability, long-term mortality and heart failure among patients undergoing catheter ablation for ventricular tachycardia (VT-CA).
Objective: To assess the validity of PAINESD score and compare outcomes of high-risk patients undergoing catheter ablation for ventricular tachycardia (VT) with and without mechanical circulatory support (MCS) use during procedure.
Methods: We conducted an observational dual-center study of consecutive patients with SHD undergoing VT-CA over a decade (2012-2022). The PAINESD score, based on 7 variables (COPD, age >60 years, general anesthesia, ischemic cardiomyopathy, NYHA class III or IV, ejection fraction <25%, VT storm, and diabetes mellitus), was calculated and categorized into low risk (<10), intermediate risk (10-16), and high risk (>16) as previously reported. Two survival analyses were performed to compare outcomes between different groups: one using all-cause mortality or heart transplant as the event, and another using recurrent or repeat ablation as the event. Multivariable Cox proportional hazards regression models were used to calculate hazard ratios for each PAINESD category and to determine the hazard ratio for the use of MCS among high-risk patients.
Results: We found that between 2012 to 2022, 559 ablations were performed on 441 patients. There were 296 (53%), 182 (32.6%) and 81(14.5%) patients in low, medium, and high risk. Using low risk as reference, aHR for medium risk was 2.1 (1.24-3.7; p=0.006) and for high risk was 4.6(2.54-8.3; p <0.001).
Among patients with high PAINESD score (n=81), 5 patients (6.2%) required MCS (Intra-arterial balloon pump (IABP)=1, ECMO only=1, ECMO+IABP=1, bypass=2). 4/5 (80%) patients on MCS stayed on them post procedure, except one patient on IABP. In this cohort, there was no difference between patients with and without MCS in primary outcome [aHR= 1.6 (0.48-5.4); p=0.43] and in secondary OUTCOME [1.29 (0.3-5.5; p=0.735)].
Conclusion: PAINESD was a significant predictor of mortality or heart failure, but it did not help in prediction of recurrence of VT, or repeat VT-CA.
Details
- Title: Subtitle
- Abstract 4147907: Validation of PAINESD Score to Predict Outcomes of Catheter ablation of Structural Ventricular Tachycardia
- Creators
- Tiffany Woelber - Mayo ClinicPragyat Futela - MetroHealthS Arunachalam Karikalan - Mayo ClinicAastha Poddar - Mayo ClinicKiyan Heybati - Mayo Clinic in Floridaaishwarya pradeep - Mayo ClinicNarut Prasitlumkum - Mayo ClinicHina Amin - Mayo ClinicAbhishek Deshmukh - Mayo ClinicGurukripa Kowlgi - Mayo Clinic
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.150(Suppl_1), pp.A4147907-A4147907
- DOI
- 10.1161/circ.150.suppl_1.4147907
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Publisher
- Lippincott Williams & Wilkins; PHILADELPHIA
- Language
- English
- Date published
- 11/12/2024
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984961023002771
Metrics
1 Record Views